Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366463229> ?p ?o ?g. }
- W4366463229 endingPage "643" @default.
- W4366463229 startingPage "628" @default.
- W4366463229 abstract "In approximately 15-20% of the patients diagnosed with breast cancer, it comprises the triple negative (TN) subtype, which until recently lacked targets for specific treatments and is known for its aggressive clinical behavior in patients with metastatic disease. TNBC is considered the most immunogenic breast cancer subtype due to higher levels of tumor infiltrating lymphocytes (TILs), tumor mutational burden and PD-L1 expression, providing a rationale for immunotherapy. The addition of pembrolizumab to chemotherapy as first-line treatment resulted in significantly improved PFS and OS for PD-L1 positive mTNBC, leading to FDA approval. However, response rate of ICB in unselected patients is low. Ongoing (pre)clinical trials aim to further optimize ICB efficacy and widen its application beyond PD-L1 positive breast tumors. Novel immunomodulatory approaches to induce a more inflamed tumor microenvironment include dual checkpoint blockade, bispecific antibodies, immunocytokines, adoptive cell therapies, oncolytic viruses, and cancer vaccines. Preclinical data for these novel strategies seems promising, but solid clinical data to further support its application for mTNBC is awaited. Biomarkers capturing the degree of immunogenicity such as but not limited to TILs, CD8 T cell levels, and IFNg signatures could support deciding which therapeutic strategy is most appropriate for which patient. Given 1) the accumulating therapy options for patients with metastatic disease and 2) the heterogeneity of mTNBC from inflamed to immune-desert tumors, the challenge is to work towards immunomodulatory strategies for specific subgroups of patients with TNBC to enable personalized (immuno)therapy for patients with metastatic disease." @default.
- W4366463229 created "2023-04-22" @default.
- W4366463229 creator A5000111147 @default.
- W4366463229 creator A5071056994 @default.
- W4366463229 date "2023-04-20" @default.
- W4366463229 modified "2023-10-01" @default.
- W4366463229 title "Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches" @default.
- W4366463229 cites W1058934875 @default.
- W4366463229 cites W1938515409 @default.
- W4366463229 cites W2051989799 @default.
- W4366463229 cites W2062601742 @default.
- W4366463229 cites W2103959341 @default.
- W4366463229 cites W2109274792 @default.
- W4366463229 cites W2112687290 @default.
- W4366463229 cites W2114505219 @default.
- W4366463229 cites W2115727543 @default.
- W4366463229 cites W2124446900 @default.
- W4366463229 cites W2139591061 @default.
- W4366463229 cites W2140634848 @default.
- W4366463229 cites W2145896038 @default.
- W4366463229 cites W2170602872 @default.
- W4366463229 cites W2172901603 @default.
- W4366463229 cites W2294393151 @default.
- W4366463229 cites W2403400382 @default.
- W4366463229 cites W2561642944 @default.
- W4366463229 cites W2562493667 @default.
- W4366463229 cites W2597045666 @default.
- W4366463229 cites W2747764243 @default.
- W4366463229 cites W2761452338 @default.
- W4366463229 cites W2766467447 @default.
- W4366463229 cites W2771978163 @default.
- W4366463229 cites W2781905683 @default.
- W4366463229 cites W2792214303 @default.
- W4366463229 cites W2797118096 @default.
- W4366463229 cites W2801821552 @default.
- W4366463229 cites W2806895459 @default.
- W4366463229 cites W2889746019 @default.
- W4366463229 cites W2890298773 @default.
- W4366463229 cites W2897422388 @default.
- W4366463229 cites W2900046418 @default.
- W4366463229 cites W2902530914 @default.
- W4366463229 cites W2905445906 @default.
- W4366463229 cites W2906932524 @default.
- W4366463229 cites W2909679049 @default.
- W4366463229 cites W2911543360 @default.
- W4366463229 cites W2944687997 @default.
- W4366463229 cites W2946054739 @default.
- W4366463229 cites W2946550606 @default.
- W4366463229 cites W2980166314 @default.
- W4366463229 cites W2991268644 @default.
- W4366463229 cites W2996238807 @default.
- W4366463229 cites W3007421866 @default.
- W4366463229 cites W3007904014 @default.
- W4366463229 cites W3013777135 @default.
- W4366463229 cites W3014771615 @default.
- W4366463229 cites W3028523516 @default.
- W4366463229 cites W3032152696 @default.
- W4366463229 cites W3046910142 @default.
- W4366463229 cites W3087393791 @default.
- W4366463229 cites W3088074323 @default.
- W4366463229 cites W3092549129 @default.
- W4366463229 cites W3093495340 @default.
- W4366463229 cites W3095316560 @default.
- W4366463229 cites W3098454574 @default.
- W4366463229 cites W3109853980 @default.
- W4366463229 cites W3123696223 @default.
- W4366463229 cites W3124720941 @default.
- W4366463229 cites W3125581240 @default.
- W4366463229 cites W3135041256 @default.
- W4366463229 cites W3146288761 @default.
- W4366463229 cites W3152698713 @default.
- W4366463229 cites W3156985612 @default.
- W4366463229 cites W3157387484 @default.
- W4366463229 cites W3167191597 @default.
- W4366463229 cites W3169973594 @default.
- W4366463229 cites W3171842402 @default.
- W4366463229 cites W3173705400 @default.
- W4366463229 cites W3174122195 @default.
- W4366463229 cites W3175173749 @default.
- W4366463229 cites W3185612921 @default.
- W4366463229 cites W3186122809 @default.
- W4366463229 cites W3201651407 @default.
- W4366463229 cites W3202723367 @default.
- W4366463229 cites W3204909328 @default.
- W4366463229 cites W3208651217 @default.
- W4366463229 cites W3217566011 @default.
- W4366463229 cites W4205837693 @default.
- W4366463229 cites W4206384730 @default.
- W4366463229 cites W4206952776 @default.
- W4366463229 cites W4214814818 @default.
- W4366463229 cites W4214927528 @default.
- W4366463229 cites W4220657093 @default.
- W4366463229 cites W4220730309 @default.
- W4366463229 cites W4220798393 @default.
- W4366463229 cites W4220963624 @default.
- W4366463229 cites W4221026889 @default.
- W4366463229 cites W4223962346 @default.
- W4366463229 cites W4224211909 @default.